Trial · NCT06926868
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | Approximately 22 months from first participant randomization in Phase 3 | Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) |
| Primary | Recommended Phase 3 Dose (RP3D) of BMS-986507 | Approximately 13 months from first participant randomization in Phase 2 | |
| Secondary | Overall Survival (OS) | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Number of participants with treatment-related Adverse Events (AEs) | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Number of participants with laboratory abnormalities | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Number of participants with serious AEs (SAEs) | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Number of participants with AEs leading to treatment discontinuation, interruption, dose reduction or dose delay | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Number of deaths | Approximately up to 47 months from first participant randomization in Phase 3 | |
| Secondary | Objective Response (OR) per BICR | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Objective Response (OR) per Investigator | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | PFS rate | Approximately 22 months from first participant randomization in Phase 3 | Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by BICR |
| Secondary | PFS rate | Approximately 22 months from first participant randomization in Phase 3 | Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by Investigator |
| Secondary | Relative change in tumor size | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Disease control rate (DCR) per BICR | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Disease control rate (DCR) per Investigator | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | PFS | Approximately 22 months from first participant randomization in Phase 3 | Assessed by Investigator |
| Secondary | Duration of Response (DOR) per BICR | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Duration of response (DOR) per Investigator | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Time to Response (TTR) per BICR | Approximately 22 months from first participant randomization in Phase 3 | |
| Secondary | Time to response (TTR) per Investigator | Approximately 22 months from first participant randomization in Phase 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06926868/registered